0001438533-26-000014
SEC filingTravere Therapeutics reported total revenue of $490.7 million for FY 2025, with a net loss of $25.5 million. The company generated positive operating cash flow of $37.8 million from continuing operations, driven by strong revenue performance and effective working capital management. Key financial highlights include an operating loss of $62.8 million, partially offset by other income of $13.6 million. The balance sheet shows total assets of $605.2 million, with cash and cash equivalents of $93.0 million and marketable debt securities of $229.8 million. Total liabilities stand at $490.4 million, including convertible debt of $311.7 million, resulting in stockholders' equity of $114.8 million. The company's comprehensive loss was $26.7 million for the period.
Travere Therapeutics reported total revenue of $490.7 million for the fiscal year ending December 31, 2025. The company recorded a net loss of $25.5 million, which includes income from discontinued operations of $24.7 million, resulting in a loss from continuing operations of $50.3 million. Operating loss was $62.8 million, with total operating expenses of $553.6 million comprising cost of goods sold ($10.3 million), research and development ($206.0 million), and selling, general and administrative expenses ($337.2 million). Other income of $13.6 million partially offset the operating loss, consisting of interest income ($12.7 million), interest expense ($10.7 million), and other income ($11.6 million).
The filing does not provide segment breakdown or geographic mix data for revenue. Total revenue of $490.7 million represents the company's consolidated performance. No specific revenue drivers or product/service breakdown is disclosed in the provided data. The absence of segment reporting suggests the company operates as a single reporting segment or has not disclosed segment-level information in this filing.
Gross margin cannot be calculated as gross profit is not explicitly stated in the provided data. Operating margin was negative at -12.8% based on operating loss of $62.8 million and revenue of $490.7 million. The cost structure shows research and development expenses of $206.0 million (42.0% of revenue) and selling, general and administrative expenses of $337.2 million (68.7% of revenue). Cost of goods sold was $10.3 million, representing 2.1% of total revenue.
Operating cash flow from continuing operations was positive at $37.8 million, driven by net loss adjustments including depreciation and amortization ($60.7 million) and share-based compensation ($44.9 million). Investing activities generated $27.9 million primarily from net proceeds from marketable debt securities transactions. Financing activities used $33.5 million mainly for repayment of convertible senior notes ($68.9 million). The balance sheet shows total assets of $605.2 million, with current assets of $437.6 million including cash ($93.0 million) and marketable securities ($229.8 million). Total liabilities of $490.4 million include convertible debt of $311.7 million, resulting in stockholders' equity of $114.8 million.
The filing does not contain forward-looking statements, management guidance, or specific strategic priorities in the provided data. No risk factors or future outlook information is included in the extracted financial statements. Investors should refer to the complete 10-K filing for management discussion and analysis, risk factors, and forward-looking statements that typically accompany these financial results.